Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.

One study failed to demonstrate pain relief in mCRPC to the bones, whereas another trial showed a trend toward improved bone progression-free survival with the use of clodronate, but the difference did not reach statistical significance. 25 , 26 A long-term follow-up of the trial showed that OS significantly favored the clodronate arm hinting to the possible antineoplastic role of the drug.

also in 111,027 other papers